Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 15289357)

  • 1. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
    Adams S; Miller GT; Jesson MI; Watanabe T; Jones B; Wallner BP
    Cancer Res; 2004 Aug; 64(15):5471-80. PubMed ID: 15289357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies.
    Jones B; Adams S; Miller GT; Jesson MI; Watanabe T; Wallner BP
    Blood; 2003 Sep; 102(5):1641-8. PubMed ID: 12738665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.
    Nemunaitis J; Vukelja SJ; Richards D; Cunningham C; Senzer N; Nugent J; Duncan H; Jones B; Haltom E; Uprichard MJ
    Cancer Invest; 2006 Oct; 24(6):553-61. PubMed ID: 16982458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
    Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
    J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.
    Connolly BA; Sanford DG; Chiluwal AK; Healey SE; Peters DE; Dimare MT; Wu W; Liu Y; Maw H; Zhou Y; Li Y; Jin Z; Sudmeier JL; Lai JH; Bachovchin WW
    J Med Chem; 2008 Oct; 51(19):6005-13. PubMed ID: 18783201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
    Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV.
    Tsu H; Chen X; Chen CT; Lee SJ; Chang CN; Kao KH; Coumar MS; Yeh YT; Chien CH; Wang HS; Lin KT; Chang YY; Wu SH; Chen YS; Lu IL; Wu SY; Tsai TY; Chen WC; Hsieh HP; Chao YS; Jiaang WT
    J Med Chem; 2006 Jan; 49(1):373-80. PubMed ID: 16392822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
    Green SK; Karlsson MC; Ravetch JV; Kerbel RS
    Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of dipeptidyl peptidase-IV activity and/or structure homologs in human meningiomas.
    Stremenová J; Mares V; Lisá V; Hilser M; Krepela E; Vanicková Z; Syrucek M; Soula O; Sedo A
    Int J Oncol; 2010 Feb; 36(2):351-8. PubMed ID: 20043068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.
    Iakoubov LZ; Torchilin VP
    Oncol Res; 1997; 9(8):439-46. PubMed ID: 9436197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective inhibitor of dipeptidyl peptidase I impairs generation of CD8+ T cell cytotoxic effector function.
    Thiele DL; McGuire MJ; Lipsky PE
    J Immunol; 1997 Jun; 158(11):5200-10. PubMed ID: 9164937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Talabostat.
    Cunningham CC
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1459-65. PubMed ID: 17714031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.